A Study of LY3819253 (LY-CoV555) in Participants Hospitalized for COVID-19

NCT04411628 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

26

Enrollment

INDUSTRY

Sponsor class

Conditions

COVID-19

Interventions

DRUG: LY3819253
DRUG: Placebo

Sponsor

Eli Lilly and Company

Collaborators

[object Object]